Histopathological subclassification of triple negative breast cancer using prognostic scoring system: Five variables as candidates

Virchows Archiv

Volumn 458, Issue 1, 2011, Pages 65-72

  Miyashita, Minoru ^a,b   Ishida, Takanori ^a   Ishida, Kazuyuki ^b   Tamaki, Kentaro ^a   Amari, Masakazu ^a   Watanabe, Mika ^b   Ohuchi, Noriaki ^a   Sasano, Hironobu ^b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Basal like; Histopathology; Ki 67; MVD; Prognosis; Triple negative breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CD31 ANTIGEN; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE; LYMPH NODE; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD31; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JAPAN; KI-67 ANTIGEN; MICROCIRCULATION; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 78651322455     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-010-1009-2     Document Type: Article

References (47)

1. CM Perou T Sorlie MB Eisen, et al. 2000 Molecular portraits of human breast tumors Nature 406 747 752 1:CAS:528:DC%2BD3cXmt1CnsLw%3D 10.1038/35021093 10963602
2. T Sorlie C Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 10869 10874 1:CAS:528:DC%2BD3MXntVGmsbo%3D 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
3. TO Nielsen FD Hsu K Jensen, et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 16 5367 5374 1:CAS:528:DC%2BD2cXmvFSlt7k%3D 10.1158/1078-0432.CCR- 04-0220 15328174 (Pubitemid 39100473)
4. CA Livasy G Karaca R Nanda, et al. 2006 Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma Mod Pathol 19 2 264 271 1:CAS:528:DC%2BD28Xlt1eqtw%3D%3D 10.1038/modpathol.3800528 16341146 (Pubitemid 43117611)
5. E Lerma G Peiro T Ramo'n, et al. 2007 Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2//neu (basal-like breast carcinomas) Mod Pathol 20 11 1200 1207 1:CAS:528:DC%2BD2sXhtFOksbzK 10.1038/modpathol.3800961 17885672 (Pubitemid 47609069)
6. JS Reis-Filho ANJ Tutt 2008 Triple negative tumours: a critical review Histopathology 52 108 118 1:STN:280:DC%2BD1c%2FgsF2mtg%3D%3D 10.1111/j.1365-2559.2007.02889.x 18171422 (Pubitemid 350265179)
7. EA Rakha ME El-Sayed AR Green, et al. 2007 Prognostic markers in triple-negative breast cancer Cancer 109 1 25 32 1:CAS:528:DC%2BD2sXhtVKrtLY%3D 10.1002/cncr.22381 17146782 (Pubitemid 46120191)
8. EA Rakha JS Reis-Filho OE Ian 2008 Basal-like breast cancer: a critical review J Clin Oncol 26 2568 2581 10.1200/JCO.2007.13.1748 18487574
9. CU-C Maggie V David B Chris, et al. 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 5 1368 1376 10.1158/1078-0432.CCR-07-1658 (Pubitemid 351413917)
10. KR Bauer M Brown RD Cress, et al. 2007 Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the socalled triple-negative phenotype: a population-based study from the California cancer registry Cancer 109 9 1721 1728 10.1002/cncr.22618 17387718 (Pubitemid 46668532)
11. LA Carey EC Dees L Sawyer, et al. 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 8 2329 2334 1:CAS:528:DC%2BD2sXkt1enur0%3D 10.1158/1078-0432.CCR-06-1109 17438091 (Pubitemid 46698581)
12. J Rhee SW Han DY Oh, et al. 2008 The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer BMC Cancer 8 1 307 10.1186/1471-2407-8-307 18947390
13. L Cornelia M Chafika RH Kenneth, et al. 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275 1281 10.1200/JCO.2007.14.4147
14. VS Anne G Nadège L Carlo, et al. 2007 Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity Breast Cancer Res 9 2 1 15 10.1186/bcr1799
15. J Jocelyne P Laetitia R Laetitia, et al. 2005 Typical medullary breast carcinomas have a basal/myoepithelial phenotype J Pathol 207 3 260 268 10.1002/path.1845 (Pubitemid 41556449)
16. B Francois F Pascal C Nathalie, et al. 2006 Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers Cancer Res 66 9 4636 4644 10.1158/0008-5472.CAN-06-0031
17. Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York, pp 131-141
18. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer: experience from a larger study with long-term follow-up Histopathology 19 403 410 1:STN:280: DyaK38%2FpvVSltw%3D%3D 10.1111/j.1365-2559.1991.tb00229.x 1757079
19. Rosen PP, Oberman H (1993) Tumors of the mammary gland. Armed Forces Institute of Pathology, Washington, DC
20. AC Wolff MH Hammond JN Schwartz, et al. 2007 American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145 1:CAS:528:DC%2BD2sXht1ejs7Y%3D 10.1200/JCO.2006.09.2775 17159189 (Pubitemid 350003059)
21. F Spyratos TM Ferrero-PM, et al. 2002 Correlation between MIB-1 and other proliferation marker clinical implications of the MIB-1 cutoff value Cancer 94 8 2151 2159 1:CAS:528:DC%2BD38Xjs12gtL8%3D 10.1002/cncr.10458 12001111 (Pubitemid 34411971)
22. N Attiqa Q Nadeem V Georges, et al. 2002 Prognostic factors in node-negative breast cancer a review of studies with sample size more than 200 and follow-up more than 5 years Ann Surg 235 10 26 10.1097/00000658-200201000- 00003 (Pubitemid 34062395)
23. U Ander ES Ian D Mitch 2005 Proliferation marker Ki-67 in early breast cancer J Clin Oncol 23 7212 7220 10.1200/JCO.2005.07.501
24. E Azambuja F Cardoso G Castro, et al. 2007 Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients Br J Cancer 96 1504 1513 10.1038/sj.bjc.6603756 17453008 (Pubitemid 46762956)
25. N Weidner JP Semple WR Welch, et al. 1991 Tumor angiogenesis and metastasis correlation in invasive breast carcinoma N Engl J Med 324 1 8 1:STN:280:DyaK3M%2FnsVWquw%3D%3D 10.1056/NEJM199101033240101 1701519
26. N Weidner J Folkman F Pozza, et al. 1992 Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma J Natl Cancer Inst 84 1875 1887 1:STN:280:DyaK3s%2FpsFWhtA%3D%3D 10.1093/jnci/84.24.1875 1281237
27. DA Morrow EM Antman A Charlesworth, et al. 2000 TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy Circulation 102 17 2031 2037 1:STN:280:DC%2BD3crgt1ensQ%3D%3D 11044416
28. JE Matthew T Yu L Jingqin, et al. 2008 Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics J Natl Cancer Inst 100 1380 1388 10.1093/jnci/djn309
29. S Wang H Yang F Tong, et al. 2009 Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer Gan To Kagaku Ryoho 36 2 255 258 19223741
30. J Hugh J Hanson MC Cheang, et al. 2009 Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial J Clin Oncol 27 8 1168 1176 1:CAS:528:DC%2BD1MXktFKhs7Y%3D 10.1200/JCO.2008.18.1024 19204205
31. A Edith A Perez T Aubrey, et al. 2010 Adjuvant therapy of triple negative breast cancer Breast Cancer Res Treat 120 285 291 10.1007/s10549-010-0736-z
32. HE Bryant N Schultz HD Thomas, et al. 2005 Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase Nature 434 7035 913 917 1:CAS:528:DC%2BD2MXjtFOmsrY%3D 10.1038/nature03443 15829966 (Pubitemid 40559005)
33. K Ratnam JA Low 2007 Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology Clin Cancer Res 13 5 1383 1388 1:CAS:528:DC%2BD2sXitlSjtr8%3D 10.1158/1078-0432.CCR-06-2260 17332279 (Pubitemid 46450426)
34. Y Yamamoto M Toi S Kondo, et al. 1996 Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients Clin Cancer Res 2 821 826 1:STN:280:DyaK1M%2FjsFSrtg%3D%3D 9816236
35. J Adams PJ Carder S Downey, et al. 2000 Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen Cancer Res 60 2898 2905 1:CAS:528:DC%2BD3cXjvFOltr8%3D 10850435
36. JA Foekens HA Peters N Grebenchtchikov, et al. 2001 High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer Cancer Res 61 5407 5414 1:CAS:528:DC%2BD3MXnsVCru7o%3D 11454684
37. BK Linderholm H Hellborg U Johansson, et al. 2009 Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer Ann Oncol 20 10 1639 1646 1:STN:280:DC%2BD1MnjvFyitQ%3D%3D 10.1093/annonc/mdp062 19549711
38. K Miller M Wang J Gralow, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D 10.1056/NEJMoa072113 18160686
39. Ryan PD, Tung NM, Isakoff SJ et al (2009) Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol 27 (Suppl). (Abstr 551)
40. H Steinbjørn AG Dorthe BS Flemming, et al. 2000 The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients Clin Cancer Res 6 139 146
41. U Bernard N Patrick C Michel, et al. 2004 Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis Cancer Res 64 2941 2955 10.1158/0008-5472.CAN-03- 0005 (Pubitemid 38120885)
42. RAA Mohammed A Green S El-Shikh, et al. 2007 Prognostic significance of vascular endothelial cell growth factors-A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis Br J Cancer 96 1092 1100 1:CAS:528:DC%2BD2sXjsleksLc%3D 10.1038/sj.bjc.6603678 17353919 (Pubitemid 46608319)
43. A Rabab O Ian E Somaia, et al. 2009 Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications Breast Cancer Res Treat 113 261 273 10.1007/s10549-008-9936-1
44. L Nair S Barbara V Daniella, et al. 2009 Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles Histopathology 55 594 599 10.1111/j.1365-2559.2009.03417.x
45. Y Nieto J Woods F Nawaz, et al. 2007 Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy Br J Cancer 97 391 397 1:CAS:528: DC%2BD2sXotlSgtro%3D 10.1038/sj.bjc.6603875 17609662 (Pubitemid 47196747)
46. MJ Acenero JF Gonzalez MG Gallego, et al. 1998 Vascular enumeration as a significant prognosticator for invasive breast carcinoma J Clin Oncol 16 1684 1688 1:STN:280:DyaK1c3ks1aqsw%3D%3D 9586879
47. B Ana E Pilar Z Rosa, et al. 2010 Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research Cancer Treat Rev 36 206 215 10.1016/j.ctrv.2009.12.002